Back to Results

Caroline C. Kim, MD Accepting New Patients

Programs + Specialties
Training + Education Harvard Medical School; Internship: Brigham and Women's Hospital Residency: Harvard Combined Dermatology Residency Program
NPI # 1386602753
Gender Female
Accepted Insurances View Accepted Insurances at Tufts Medical Center

Tufts Medical Center
Biewend Building, 13th Floor
260 Tremont Street
Boston, MA 02111
Phone #: 617-636-0156
Fax #: 617-636-9169

Strazzulla LC, Li X, Zhu K, Okhovat JP, Lee SJ, Kim CC. Clinicopathologic, misdiagnosis and survival differences between clinically amelanotic melanomas and pigmented melanomas.

Kim CC, Berry EG, Marchetti MA, Swetter SM, Lim G, Grossman D, Curiel-Lewandrowski C, Chu EY, Ming ME, Zhu K, Brahmbhatt M, Balakrishnan V, Davis MJ, Mus B, Wolner Z, Fleming N, Ferris LK, Nguyen J, Trofymenko O, Liu Y, Chen SC. Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but with Positive Histologic Margins. JAMA Dermatology 2018 Oct. 10. Doi:10.1001/jamadermatol.2018.3359

Tan S, Strazzulla L, Li X, Park J, Lee S, and Kim CC. The association of clinicopathologic features of melanoma with total nevus count and a history of dysplastic nevi: a cross-sectional retrospective study within an academic center. Clinical and Experimental Dermatology. 2018 Feb 16.

Nelson K, Grossman G, Kim CC, Chen SC, Curiel-Lewandrowski C, Grichnik JM, Kirkwood JM, Leachman SA, Marghoob AA, Swetter SM, Venna SS, Ming ME. Management strategies of American academic pigmented lesion clinic directors. J Am Acad Dermatol. 2018 Jan 4. Pli:S0180-9622(18)30011-2.doi: 10.1016/j.jaad.2017.12.069.

Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC*, Grossman D. Reduction in nevus biopsies in patients monitored by total body photography. J Am Acad Dermatol. 2016 Jul;75(1):135-143.e5.

Tong LX, Wu PA, Kim, CC. Degree of clinical concern and dysplasia affect biopsy technique and management of dysplastic nevi with positive biopsy margins: Results from a survey of New England Dermatologists. J Am Acad Dermatol. 2016 Feb;74(2):389-391.e2. doi: 10.1016/j.jaad.2015.09.055.

Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schandendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL and Joe AK. Analysis of Dermatologic Events in Vemurafenib-treated Melanoma Patients. Oncologist. 2013;18(3):314-22. Epub 2013.Mar 1.

Bielenberg DR, Hida Y, Shimiz A, Kaipainene A, Kreuter M, Kim CC, and Klagsbrun M. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. Journal of Clinical Investigations. 2004;114(9):1260-1271.

Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E and Klagsbrun M. Characterization of a naturally occurring ErbB4 Isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene. 1999;18:2607-2615.

Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman G and Klagsbrun M. A Novel Juxtamembrane Domain Isoform of HER4/ErbB4. Journal of Biological Chemistry. 1997;272(42):26761-26768.

Massachusetts Medical Society
American Medical Association
Society of Pediatric Dermatology
American Academy of Dermatology